Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses the goals of the SystHERs Registry.
Clinical Pearls:
- This registry will enroll patients who have been diagnosed with HER2/neu-positive metastatic breast cancer within the last 6 months.
- The registry will collect detailed information on patients who are diagnosed with HER2 metastatic breast cancer to look both at the demographic factors as well as their past history.
- The registry will also look at what treatment they receive in the metastatic setting, what their outcomes are in terms of response and side effects.
- This will help researchers better understand how patients react to new agents that have been developed in this space.